ADPT - Adaptive Biotechnologies Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Seattle,
United States
Type: Equity
ADPT price evolution
ADPT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $62.8 | $74.2 | $68 | |
| Short term investments | $232.06 | $237.64 | $281.34 | |
| Net receivables | $40.81 | $35.61 | $42.02 | $37.97 |
| Inventory | $11.96 | $13.21 | $13.29 | $14.45 |
| Total current assets | $308.35 | $351.55 | $374.03 | $410.19 |
| Long term investments | ||||
| Property, plant & equipment | $97.84 | $103.94 | $116.26 | $120.32 |
| Goodwill & intangible assets | $123.25 | $123.68 | $124.1 | |
| Total noncurrent assets | $233.32 | $246.29 | $250.95 | |
| Total investments | $232.06 | $237.64 | $281.34 | |
| Total assets | $558.51 | $584.87 | $620.32 | $661.13 |
| Current liabilities | ||||
| Accounts payable | $7.35 | $9.87 | $12.17 | $7.72 |
| Deferred revenue | $91.07 | $91.03 | $93.42 | |
| Short long term debt | $9.81 | $9.59 | $9.38 | |
| Total current liabilities | $87.63 | $88.13 | $82.95 | $88.02 |
| Long term debt | $132.7 | $216.45 | $218.44 | $220.05 |
| Total noncurrent liabilities | $255.32 | $262.61 | $264.84 | |
| Total debt | $226.26 | $228.04 | $229.43 | |
| Total liabilities | $334.73 | $343.44 | $345.56 | $352.86 |
| Shareholders' equity | ||||
| Retained earnings | -$1270.13 | -$1238.06 | -$1191.84 | -$1144.33 |
| Other shareholder equity | $0.5 | -$0.18 | -$0.11 | $0.21 |
| Total shareholder equity | $241.6 | $274.91 | $308.4 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $68 | $92.43 | $141.2 | $125.57 |
| Short term investments | $281.34 | $408.17 | $214 | $564.83 |
| Net receivables | $37.97 | $40.06 | $17.41 | $10.05 |
| Inventory | $14.45 | $14.45 | $19.26 | $14.06 |
| Total current assets | $410.19 | $562.15 | $402.75 | $726.91 |
| Long term investments | $217.15 | $118.53 | ||
| Property, plant & equipment | $120.32 | $164.21 | $172.94 | $139.04 |
| Goodwill & intangible assets | $124.1 | $125.8 | $127.5 | $129.2 |
| Total noncurrent assets | $250.95 | $294.47 | $520.6 | $389.5 |
| Total investments | $281.34 | $408.17 | $431.14 | $683.36 |
| Total assets | $661.13 | $856.62 | $923.34 | $1116.41 |
| Current liabilities | ||||
| Accounts payable | $7.72 | $8.08 | $3.31 | $3.24 |
| Deferred revenue | $93.42 | $122.71 | $179.21 | $236.94 |
| Short long term debt | $9.38 | $9.23 | $5.05 | $3.53 |
| Total current liabilities | $88.02 | $109.79 | $113.81 | $105.2 |
| Long term debt | $220.05 | $125.36 | $106.69 | $104.33 |
| Total noncurrent liabilities | $264.84 | $282.73 | $205.44 | $267.95 |
| Total debt | $229.43 | $233.36 | $111.74 | $107.86 |
| Total liabilities | $352.86 | $392.45 | $319.24 | $373.15 |
| Shareholders' equity | ||||
| Retained earnings | -$1144.33 | -$919.08 | -$718.89 | -$511.61 |
| Other shareholder equity | $0.21 | -$4.12 | -$1.14 | $0.89 |
| Total shareholder equity | $308.4 | $464.17 | $603.99 | $743.27 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $43.19 | $41.87 | $45.78 | |
| Cost of revenue | $19.32 | $18.05 | $19.62 | |
| Gross Profit | $23.87 | $23.82 | $26.17 | |
| Operating activities | ||||
| Research & development | $25.35 | $30.25 | $28.75 | |
| Selling, general & administrative | $38.21 | $41.92 | $42.63 | |
| Total operating expenses | $71.19 | $72.58 | $97.24 | |
| Operating income | -$47.32 | -$48.76 | -$71.07 | |
| Income from continuing operations | ||||
| EBIT | -$43.53 | -$44.51 | -$66.43 | |
| Income tax expense | ||||
| Interest expense | $2.7 | $2.99 | $3.01 | |
| Net income | ||||
| Net income | -$46.22 | -$47.51 | -$69.44 | |
| Income (for common shares) | -$46.22 | -$47.51 | -$69.44 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $170.28 | $185.31 | $154.34 | $98.38 |
| Cost of revenue | $75.55 | $57.91 | $49.3 | $22.53 |
| Gross Profit | $94.72 | $127.4 | $105.04 | $75.85 |
| Operating activities | ||||
| Research & development | $122.12 | $141.76 | $142.34 | $116.07 |
| Selling, general & administrative | $172.51 | $184.13 | $169.97 | $110.89 |
| Total operating expenses | $321.76 | $327.58 | $314.01 | $228.67 |
| Operating income | -$227.03 | -$200.19 | -$208.97 | -$152.82 |
| Income from continuing operations | ||||
| EBIT | -$211.45 | -$195.95 | -$207.28 | -$146.23 |
| Income tax expense | ||||
| Interest expense | $13.8 | $4.24 | ||
| Net income | ||||
| Net income | -$225.25 | -$200.19 | -$207.28 | -$146.23 |
| Income (for common shares) | -$225.25 | -$200.19 | -$207.28 | -$146.23 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$46.22 | -$47.51 | -$69.44 | |
| Operating activities | ||||
| Depreciation | $6.35 | $6.58 | $6.82 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $12.96 | $14.3 | $15.56 | |
| Total cash flows from operations | -$17.3 | -$38.35 | -$26.93 | |
| Investing activities | ||||
| Capital expenditures | -$1.73 | -$1.51 | -$1.3 | |
| Investments | $7.61 | $46.02 | $4.5 | |
| Total cash flows from investing | $55.67 | $5.88 | $44.51 | $3.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.03 | $0.04 | $0.09 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.11 | $0.03 | $0.04 | $0.09 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$26.93 | -$11.4 | $6.2 | -$23.64 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$225.25 | -$200.19 | -$207.28 | -$146.23 |
| Operating activities | ||||
| Depreciation | $29.15 | $28.15 | $20.98 | $11.74 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $62.91 | $55.48 | $43.25 | $24.76 |
| Total cash flows from operations | -$156.32 | -$183.94 | -$192.73 | -$149.68 |
| Investing activities | ||||
| Capital expenditures | -$10.7 | -$16.35 | -$61.75 | -$18.8 |
| Investments | $140.34 | $19.25 | $242.96 | -$98.24 |
| Total cash flows from investing | $129.65 | $2.9 | $181.21 | -$117.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.25 | $7.89 | $26.72 | $293.91 |
| Net borrowings | $124.38 | |||
| Total cash flows from financing | $2.25 | $132.26 | $27.15 | $293.59 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$24.43 | -$48.77 | $15.63 | $26.86 |
News
Fundamentals
| Market cap | $942.92M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 147.56M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.14 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.52 |
| Quick ratio | 3.38 |